B细胞恶性肿瘤-话题@MedSci

#B细胞恶性肿瘤#

13篇内容 | 902人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2183198, encodeId=26e3218319888, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a> <a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a> <a href='/topic/show?id=b2434060d8' target=_blank style='color:#2F92EE;'>#CAR-NK#</a>, objectTitle=Nat Med：临床研究表明靶向CD19的脐带血衍生CAR-NK细胞有望治疗多种B细胞恶性肿瘤, objectType=article, longId=809981, objectId=e37d809981bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240118/1705587350504_2185383.png, objectUrl=/article/show_article.do?id=e37d809981bc, replyNumber=0, likeNumber=15, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1506221, encodeId=7b45150622166, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, objectType=article, longId=214948, objectId=920821494873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920821494873, replyNumber=0, likeNumber=54, createdTime=2021-07-29, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920821494873, moduleTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920821494873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506220, encodeId=a0c715062202a, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=52, createdTime=2021-07-29, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506219, encodeId=12071506219d7, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素, objectType=article, longId=201329, objectId=4e25201329bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e25201329bf, replyNumber=0, likeNumber=60, createdTime=2020-09-30, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e25201329bf, moduleTitle=Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e25201329bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506218, encodeId=b2eb150621847, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, objectType=article, longId=199630, objectId=6d341996303b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d341996303b, replyNumber=0, likeNumber=50, createdTime=2020-08-19, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d341996303b, moduleTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d341996303b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506217, encodeId=ebfb150621e3f, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发, objectType=article, longId=182246, objectId=c8d018224602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8d018224602, replyNumber=0, likeNumber=55, createdTime=2019-11-03, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8d018224602, moduleTitle=Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8d018224602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506216, encodeId=94f0150621627, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, objectType=article, longId=180381, objectId=e0141803814a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0141803814a, replyNumber=0, likeNumber=59, createdTime=2019-10-03, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0141803814a, moduleTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0141803814a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506215, encodeId=4782150621577, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）, objectType=article, longId=179896, objectId=248a1e9896b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=248a1e9896b0, replyNumber=0, likeNumber=0, createdTime=2019-09-24, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=248a1e9896b0, moduleTitle=伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=248a1e9896b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506214, encodeId=c4ba1506214a4, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤, objectType=article, longId=140766, objectId=ed6f140e66a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed6f140e66a3, replyNumber=0, likeNumber=46, createdTime=2018-06-15, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed6f140e66a3, moduleTitle=Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed6f140e66a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506213, encodeId=f78a1506213d8, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=CLIN CANCER RES：BAFF受体抗体治疗耐药性B细胞恶性肿瘤, objectType=article, longId=131828, objectId=5b4e13182871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4e13182871, replyNumber=0, likeNumber=47, createdTime=2018-03-10, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4e13182871, moduleTitle=CLIN CANCER RES：BAFF受体抗体治疗耐药性B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4e13182871)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506212, encodeId=519215062126f, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=CLIN CANCER RES：靶向PI3Kδ治疗成熟B细胞恶性肿瘤, objectType=article, longId=131821, objectId=01dc131821b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01dc131821b8, replyNumber=0, likeNumber=49, createdTime=2018-03-10, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01dc131821b8, moduleTitle=CLIN CANCER RES：靶向PI3Kδ治疗成熟B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01dc131821b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506211, encodeId=ecd61506211f0, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, objectType=article, longId=116540, objectId=d02a116540e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02a116540e5, replyNumber=0, likeNumber=55, createdTime=2017-10-19, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02a116540e5, moduleTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02a116540e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506210, encodeId=20291506210ef, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=征服血癌不是梦：吉利德成功建立B细胞恶性肿瘤4个独特信号通路资产, objectType=article, longId=44498, objectId=f0854449897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0854449897, replyNumber=0, likeNumber=73, createdTime=2014-12-25, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0854449897, moduleTitle=征服血癌不是梦：吉利德成功建立B细胞恶性肿瘤4个独特信号通路资产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0854449897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506209, encodeId=bf3d1506209bb, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, objectTitle=Cancer Res.:抑制Stat3可强化对B细胞恶性肿瘤的免疫, objectType=article, longId=7400, objectId=8953e4004c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8953e4004c, replyNumber=0, likeNumber=78, createdTime=2012-06-28, rootId=0, userName=chenzhuanggui, userId=55409728490, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8953e4004c, moduleTitle=Cancer Res.:抑制Stat3可强化对B细胞恶性肿瘤的免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8953e4004c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞恶性肿瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤# #CD19# #CAR-NK#

2024-01-22发表于上海

爆笑小医 (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤

2021-07-29

爆笑小医 (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-07-29

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素

2020-09-30

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘

2020-08-19

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发

2019-11-03

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失

2019-10-03

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）

2019-09-24

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤

2018-06-15

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

CLIN CANCER RES：BAFF受体抗体治疗耐药性B细胞恶性肿瘤

2018-03-10

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

CLIN CANCER RES：靶向PI3Kδ治疗成熟B细胞恶性肿瘤

2018-03-10

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性

2017-10-19

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

征服血癌不是梦：吉利德成功建立B细胞恶性肿瘤4个独特信号通路资产

2014-12-25

chenzhuanggui (审核中...)

前往app查看评论内容

#B细胞恶性肿瘤#

Cancer Res.:抑制Stat3可强化对B细胞恶性肿瘤的免疫

2012-06-28

科室
- - 订阅+
  - 更多科室
工具
服务